Skip to main content
. 2020 Apr 9;35:101664. doi: 10.1016/j.tmaid.2020.101664

Table 2.

Comparison of Laboratory data and Outcome of Patients with COVID-19 Within and Outside Wuhan.

Guangzhou#1 (N = 20) Wuhan#2 (N = 99) P values
Blood routine
Leucocytes ( × 109/L, normal range 3.5–9.5) 5.2 (1.6) 7.5 (3.6) 0.006
Lymphocytes ( × 109/L, normal range 1.1–3.2) 1.4 (0.7) 0.9 (0.5) 0.003
Platelets ( × 109/L, normal range 125.0–350.0) 205.0 (62.6) 213.5 (79.1) 0.652
Hemoglobin (g/L, normal range 130.0–175.0)
139.3 (15.3)
129.8 (14.8)
0.010
Blood biochemistry
Increased alanine aminotransferase 4 (20.0%) 28 (28.3%) 0.584
Increased aspartate aminotransferase 3 (15.0%) 35 (35.4%) 0.113
Increased total bilirubin 1 (5.0%) 18 (18.2%) 0.192
Albumin (g/L) 44.8 (5.6) 31.6 (4.0) <0.001
 Decreased 1 (5.0%) 97 (98.0%) <0.001
Increased serum creatinine 1 (5.0%) 3 (3.0%) 0.526
Increased creatine kinase 5 (25.0%) 13 (13.1%) 0.183
Increased myoglobin
2/17 (11.8%)
15 (15.2%)
1.000
Infection-related biomarkers
Erythrocyte sedimentation rate (mm/h, normal range 0–15) 19.3 (13.2) 49.9 (23.4) <0.001
C-reaction protein (mg/L, normal range 0–6) 25.0 (29.3) 51.4 (41.8) 0.002
Procalcitonin (ng/mL, normal range 0–0.05)
0.08 (0.09)
0.5 (1.1)
<0.001
Chest X-ray and CT finding
Unilateral pneumonia 2 (10.0%) 25 (25.3%) 0.239
Bilateral pneumonia 18 (90.0%) 74 (74.7%) 0.239
Multiple mottling and ground-glass opacity 12 (60.0%) 14 (14.1%) <0.001
Peripheral pneumonia 17 (85.0%) NA NA
interstitial lesions 16 (80.0%) NA NA
Ground-glass opacity 16 (80.0%) NA NA
Multiple patches 18 (90.0%) NA NA
Multiple Infiltration 11 (55.0%) NA NA
Nodule 4 (20.0%) NA NA
Lung consolidation 4 (20.0%) NA NA
Pleural effusion 2 (10.0%) NA NA

Data are n (%) and mean (SD). N is the total number of patients with available data. COVID-19 = coronavirus disease −2019 P values for comparing two groups were derived using Fisher's exact test for categorized variables and t-test for continuous variables.

#1 Admitted to the Third Affiliated Hospital of Sun Yat-Sen University in Guangzhou from January 22 to February 12, 2020, the last follow-up was on February 18, 2020.

#2 Diagnosed in Wuhan Jinyintan Hospital from January 1 to January 20, 2020, the last follow-up was on January 25, 2020.

NA, not available.